ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Shield Therapeutics PLC (QB)

Shield Therapeutics PLC (QB) (SHIEF)

0.034
0.00
(0.00%)
Cerrado 26 Febrero 3:00PM
Gráfico avanzado

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
0.034
Postura de Compra
0.0001
Postura de Venta
1,000.05
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.0135 Rango de 52 semanas 0.0614
Capitalización de Mercado [m]
Precio Anterior
0.034
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
3,007
Acciones en circulación
1,041,690,484
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.08
Beneficio por acción (BPA)
-0.03
turnover
13.09M
Beneficio neto
-33.29M

Acerca de Shield Therapeutics PLC (QB)

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Newcastle Upon Tyne, Gbr
Fundado
-
Shield Therapeutics PLC (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker SHIEF. The last closing price for Shield Therapeutics (QB) was US$0.03. Over the last year, Shield Therapeutics (QB) shares have traded in a share price range of US$ 0.0135 to US$ 0.0614.

Shield Therapeutics (QB) currently has 1,041,690,484 shares in issue. The market capitalisation of Shield Therapeutics (QB) is US$35.42 million. Shield Therapeutics (QB) has a price to earnings ratio (PE ratio) of -1.08.

SHIEF Últimas noticias

No news to show yet.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
4000.0340.0340.03440200.034CS
12-0.0015-4.225352112680.03550.03550.03430070.03438803CS
26-0.026-43.33333333330.060.06140.034152520.05538373CS
520.00517.24137931030.0290.06140.01351265140.02237661CS
156-0.226-86.92307692310.260.260.0135558690.05237598CS
260-1.096-96.99115044251.131.50.0135360760.07624151CS

SHIEF - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Shield Therapeutics (QB)?
El precio actual de las acciones de Shield Therapeutics (QB) es US$ 0.034
¿Cuántas acciones de Shield Therapeutics (QB) están en circulación?
Shield Therapeutics (QB) tiene 1,041,690,484 acciones en circulación
¿Cuál es la capitalización de mercado de Shield Therapeutics (QB)?
La capitalización de mercado de Shield Therapeutics (QB) es USD 35.42M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Shield Therapeutics (QB)?
Shield Therapeutics (QB) ha negociado en un rango de US$ 0.0135 a US$ 0.0614 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Shield Therapeutics (QB)?
El ratio precio/beneficio de Shield Therapeutics (QB) es -1.08
¿Cuál es el ratio de efectivo a ventas de Shield Therapeutics (QB)?
El ratio de efectivo a ventas de Shield Therapeutics (QB) es 2.74
¿Cuál es la moneda de reporte de Shield Therapeutics (QB)?
Shield Therapeutics (QB) presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Shield Therapeutics (QB)?
El último ingresos anual de Shield Therapeutics (QB) es USD 13.09M
¿Cuál es el último beneficio anual de Shield Therapeutics (QB)?
El último beneficio anual de Shield Therapeutics (QB) es USD -33.29M
¿Cuál es la dirección registrada de Shield Therapeutics (QB)?
La dirección registrada de Shield Therapeutics (QB) es NORTHERN DESIGN CENTRE, BALTIC BUSINESS QUARTER, GATESHEAD QUAYS, NEWCASTLE UPON TYNE, NE8 3DF
¿Cuál es la dirección del sitio web de Shield Therapeutics (QB)?
La dirección del sitio web de Shield Therapeutics (QB) es www.shieldtherapeutics.com
¿En qué sector industrial opera Shield Therapeutics (QB)?
Shield Therapeutics (QB) opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
SCPSScopus BioPharma Inc (CE)
US$ 0.0003
(29,900.00%)
1.32k
FBECFBEC Worldwide Inc (CE)
US$ 0.0002
(19,900.00%)
35.45k
IMTLImage Protect Inc (PK)
US$ 0.0001
(9,900.00%)
46.72M
OBSEFObsEva SA (CE)
US$ 0.01
(9,900.00%)
150
TTCFQTattooed Chef Inc (CE)
US$ 0.0001
(9,900.00%)
17.53k
CULMFCulico Metals Inc (CE)
US$ 0.000001
(-100.00%)
97.6k
ULGXUrologix Inc (CE)
US$ 0.000001
(-100.00%)
7.5k
AAGRAfrican Agriculture Holdings Inc (CE)
US$ 0.000001
(-99.99%)
406
QOEGQuality Online Education Group Inc (CE)
US$ 0.000001
(-99.89%)
100
TTCMTautachrome Inc (CE)
US$ 0.000001
(-99.50%)
59.2k
HMBLHUMBL Inc (PK)
US$ 0.0005
(25.00%)
259.83M
RITEMineralRite Corporation (PK)
US$ 0.0011
(-38.89%)
155.56M
TPTWTPT Global Tech Inc (PK)
US$ 0.0002
(-33.33%)
136.62M
SPZISpooz Inc (PK)
US$ 0.0011
(-12.00%)
122.45M
RONNRonn Motor Group Inc (PK)
US$ 0.0003
(0.00%)
106.36M

SHIEF Finanzas

Finanzas

SHIEF Discussion

Ver más
makinezmoney makinezmoney 3 años hace
$SHIEF: Accrufer accepted by Health Canada

https://twitter.com/VOXmarkets/status/1547461511815258113?s=20&t=m-o2gcJ4-ZdMB9HmkL91Cg

Last price at $0.075


Watching with interest here.



https://www.shieldtherapeutics.com/wp-content/uploads/2022/03/STX-IMC-presentation-March-2022.pdf


GO $SHIEF

*********************************************************************************

Shield Therapeutics plc
("Shield" or the “Company" or the “Group”)
Accrufer® New Drug Submission accepted by Health Canada
NDS filed by Partner, KYE Pharmaceuticals Inc., for Regulatory Review has been accepted
Marketing approval expected mid-2023
London, UK – 14 July 2022: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a
focus on treating iron deficiency with its lead product Accrufer®/Feraccru®, announces that Health Canada have
screened and accepted the Accrufer® New Drug Submission (“NDS”), filed by Shield’s Licensing Partner, KYE
Pharmaceuticals Inc. (“KYE”) earlier this year.
Health Canada are expected to complete their regulatory review in mid-2023 and a successful outcome will allow
KYE to market Accrufer® in Canada. Shield will be responsible for all manufacturing and supply to the Canadian
market.
Upon regulatory approval of Accrufer® by Health Canada, Shield is due to receive a £250,000 milestone payment.
In addition, Shield would be eligible for an additional £600,000 in milestone payments upon the achievement of
specified calendar net sales targets. For the term of the agreement, Shield will also receive double-digit royalties
on net sales of Accrufer®.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Christopher Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/ George Dollemore/Alice
Lane/Nigel Birks
+44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR
Lianne Applegarth/Alice Woodings +44 (0)20 7933 8780 or shield@walbrookpr.com
Investor Contact (US Advisor)
LifeSci Advisors, LLC
John Mullaly +1 617 429 3548 or jmullaly@lifesciadvisors.com
About Accrufer®/Feraccru®
Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency,
with or without anemia. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron
therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More
information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and
www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its
lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is
commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and
New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for
the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with
Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group
👍️0